연구 및 보고서

LigaChemBio presented its ADC platform competitiveness and updates on HER2, hematologic, gastrointestinal and sarcoma pipelines during the Global R&D Day in Seoul.

The American Society of Clinical Oncology held ASCO Breakthrough 2026 in Singapore, highlighting abstracts on blood‑based multi‑cancer screening, HER2‑positive breast cancer therapies, PIK3CA‑mutated breast cancer precision treatment, early palliative care, and GLP‑1 agonist colon cancer prevention.

Huons reported first patient enrollment in the Phase 2 study of its peptide‑based dry‑eye candidate HUC1‑394, targeting 150 patients across Korean hospitals.

A US study reports that recipients of varicella, COVID‑19, HPV and shingles vaccines have a markedly lower risk of developing idiopathic uveitis, with varicella showing the strongest effect.

Migraine is a chronic, episodic headache disorder linked to mental health issues and reduced productivity, especially among adults aged 30‑50, creating a notable socioeconomic impact.

Korea's pharma and biotech firms focus on July events including R&D disclosures, FDA submissions, clinical data and Q2 earnings, with analysts watching a potential sector re‑evaluation.

WELT, a digital pharma company spun off from Samsung Electronics, celebrates its 10th year and declares a shift to AI‑combined digital convergent medicines, highlighting its SleepQ approval and new AI platforms Dr. SAM and DrugOS™.

Emerging targeted drugs are shifting atopic dermatitis care from symptom control to broader quality‑of‑life improvements.

Korean research suggests glycerol, a common cosmetic moisturizer, may slow dehydration and support performance during prolonged exercise such as marathons or soccer matches.

A study published in The Lancet Healthy Longevity finds that managing modifiable risk factors can significantly reduce dementia risk, highlighting need for personalized approaches.

A US study of 355,000 adults over 13 years found frequent coffee drinkers had better liver health indicators and reduced disease risk.

Ireland pledged €12.5 million to WHO to accelerate affordable assistive technology, targeting 2.5 billion people worldwide through digital solutions and training.